



10594620 - GAU: 1657

PTO/SB/08a (07-05) Approved for use through 07/31/2008. OMB 0851-0031

Approved for use through 07/23/2008. OMB 0051-0651
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|---|--------------------------|----------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/594,620 |
| | | Filing Date | June 27, 2007 |
| | | First Named Inventor | MOORE, Jonni |
| | | Art Unit | 1466 165 / |
| | | Examiner Name | Paul C. Martin |
| (use as many sheets as necessary) | | | |
| Sheet | 1 | of | 4 |
| | | Attorney Docket Number | P-7671-US |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|---------------|--------------------|------------|
| Examiner Signature | /Paul Martin/ | Date Considered | 06/01/2009 |
|-----------------------|---------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600.
Considered. Include copy of this form when next communication to applicant. *Applicant's unique citation designation line number (optional).
*Kinds Codes of reference: A=Art. B=Patent, C=PTO, D=Other, E=Non-patent, F=Journal, G=Book, H=Other
*Priority date: If claim(s) are based on a foreign application, indicate the country and date of filing.
*Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document
by the appropriate symbols as indicated on the document under WIPO Standard ST 1 if possible.
*Applicant is to place a check mark here if English language

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./

Approved for use through 06/20/2006. GMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|----------------|
| Substitute for form 1449B/PTO | | <i>Complete if Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/594,620 |
| | | Filing Date | June 27, 2007 |
| | | First Named Inventor | MOORE, Jonni |
| | | Art Unit | 1606 1657 |
| (use as many sheets as necessary) | | Examiner Name | Paul C. Martin |
| Sheet | 2 | of | 4 |
| Attorney Docket Number P-7671-US | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--|--|----------------|
| Examiner initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| B | AMICOSANTE M, et al. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 59. <i>Hum Immunol</i> 2001;62:686-693. | | |
| C | APPAY V, et al. Characterization of CD4(p) CTLs ex vivo. <i>J Immunol</i> 2002;168:5954-5958. | | |
| D | BARNA BP et al. Clinical application to Beryllium Lymphocyte Proliferation Testing. <i>Clin Diagn Lab Immunol</i> 2003;10:990-994. | | |
| E | BARTELL SM, et al. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. <i>Risk Anal</i> 2000;20:87-99. | | |
| F | BERNARD S, et al. Analysis of cell kinetics using a cell division marker: Mathematical modeling of experimental data. <i>Biophys J</i> 2003;84:3414-3424. | | |
| G | BILL JR, et al. Beryllium presentation to CD4p T cells is dependent on a single amino acid residue of the MHC class II beta-chain. <i>J Immunol</i> 2005;175:7029-7037. | | |
| H | DEUBNER D, et al. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. <i>Appl Occup Environ Hyg</i> 2001;16:579-592. | | |
| I | DEUBNER DC, et al. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): Preliminary analysis of the ongoing workforce survey. <i>Appl Occup Environ Hyg</i> 2001;16:521-526. | | |
| J | FARRIS GM, et al. Detection of Beryllium sensitivity using a flow cytometric lymphocyte proliferation test: The Immuno-Be-LPT. <i>Toxicology</i> 2000;143:125-140. | | |
| K | FONTENOT AP, et al. Frequency of beryllium-specific, central memory CD4p T cells in blood determines proliferative response. <i>J Clin Invest</i> 2005;115:2886-2893. | | |
| L | GIVAN AL, et al. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. <i>J Immunol Methods</i> 1999;230:99-112. | | |
| M | HENNEBERGER PK, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. <i>Int Arch Occup Environ Health</i> 2001;74:167-176. | | |
| N | HENNEBERGER PK, et al. Industries in the United States with airborne beryllium exposure and estimates of the numbers of current workers potentially exposed. <i>J Occup Environ Hyg</i> 2004;1:648-659 | | |
| O | JANEWAY CA Jr, et al. CD4p T cells: Specificity and function. <i>Immunol Rev</i> 1988;101:39-80. | | |
| P | KREISS K, et al. Chronic beryllium disease—From the workplace to cellular immunology, molecular immunogenetics, and back. <i>Clin Immunol Immunopathol</i> 1994;71:123-129. | | |
| Q | KREISS K, et al. Screening blood test identifies subclinical beryllium disease. <i>J Occup Med</i> 1989;31:603-608 | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Paul Martin/ | Date Considered | 06/01/2009 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Collection is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time estimates may vary based on numerous factors. Any comments on the amount of time you believe to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/058 (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|----------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/594,620 |
| (use as many sheets as necessary) | | | | Filing Date | June 27, 2007 |
| Sheet | 3 | of | 4 | First Named Inventor | MOORE, Jonni |
| | | | | Art Unit | 1666 1657 |
| | | | | Examiner Name | Paul C. Martin |
| | | | | Attorney Docket Number | P-7671-US |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|---|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| R | LEH-INSERT NM, et al. Inhibition of normal human lung fibroblast growth by beryllium.. Toxicology 2001 ;160:119-127. | | | | |
| S | LYONS AB, Hasbold J, Hodgkin PD. Flow cytometric analysis of cell division history using dilution of carboxyfluorescein diacetate succinimidyl ester, a stably integrated fluorescent probe. Methods Cell Biol 2001;63:375-398. | | | | |
| T | LYONS AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000;243:147-154. | | | | |
| U | LYONS AB. Divided we stand: Tracing cell proliferation with carboxy-fluorescein diacetate succinimidyl ester. Immunol Cell Biol 1999;77:509-515. | | | | |
| V | MAIER LA. Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 2001;16:514-520. | | | | |
| W | MAIER LA. Clinical approach to chronic beryllium disease and other non pneumoconiotic interstitial lung diseases. J Thorac Imaging 2002;17:273-284. | | | | |
| X | MAIER LA. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med 2002;23:827-839. | | | | |
| Y | MCCANLIES EC, et al HLA-DPB1 and chronic beryllium disease: A HuGE review.. Am J Epidemiol 2003; 157:388-398. | | | | |
| Z | MILOVANOVIA T, et al Flow Cytometric Test for Beryllium Sensitivity. Cytometry part B Clinical Cytometry 2004;60:23-30. | | | | |
| AA | NEWMAN LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996;104 (Suppl 5):953-958. | | | | |
| AB | NIKOLAEVA N, et al. Differentiation of human alloreactive CD4 β and CD8 β T cells invitro. Transplantation 2004;78:815-824. | | | | |
| AC | ROSSMAN MD, et al Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med 1988;108:687-693. | | | | |
| AD | ROSSMAN MD. Chronic beryllium disease: Diagnosis and management. Environ Health Perspect 1996;104 (Suppl 5):945-947. | | | | |
| AE | ROSSMAN MD. Chronic beryllium disease: A hypersensitivity disorder. Appl Occup Environ Hyg 2001;16:615-618. | | | | |
| AF | SALTINI C, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989;320:1103-1109. | | | | |
| AG | SAWYER RT, et al. Beryllium-induced TNF-(alpha) production by CD4 β T Cells is mediated by HLA-DR. Am J Respir Crit Care Med 2004;31:122-130. | | | | |
| AH | SPITZER RL, et al. Quantification of agreement in psychiatric diagnosis. A new approach. Arch Gen Psychiatry 1967;17:83-87. | | | | |
| AI | STANGE AW, et al. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001;16:405-417. | | | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Paul Martin/ | Date Considered | 06/01/2009 |
|--------------------|---------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11. This collection is estimated to take 2 hours to complete, including gathering, preparing, reviewing, and maintaining the completed application form in the USPTO. This will vary depending upon the individual case. The burden estimate does not include the time for preparing forms or for completing them. This burden sheet is to be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (07-05)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|----------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/594,620 |
| | | | | Filing Date | June 27, 2007 |
| | | | | First Named Inventor | MOORE, Jonni |
| | | | | Art Unit | 1666 1657 |
| (use as many sheets as necessary) | | | | | |
| Sheet | 4 | of | 4 | Examiner Name | Paul C. Martin |
| | | | | Attorney Docket Number | P-7671-US |

NON-PATENT LITERATURE DOCUMENTS

| | | | |
|-----------------------|---------------|--------------------|------------|
| Examiner Signature | /Paul Martin/ | Date Considered | 06/01/2009 |
|-----------------------|---------------|--------------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3 Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, by gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./